#62023TJ1182Genel Mahkeme (Dördüncü Daire) Kararı, 11 Şubat 2026.
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
The General Court ruled that the European Commission revoked the marketing authorization for Dimethyl Fumarate Neuraxpharm, a medicine intended for human use. This decision affects Neuraxpharm Pharmaceuticals and may impact patients relying on this medication. The ruling is based on compliance with European medicinal product regulations.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Revocation of marketing authorization for Dimethyl Fumarate Neuraxpharm
- Compliance with Directive 2001/83/EC and Regulation (EC) No 726/2004
- Impact on availability of the medication for patients
+ 1 more changes with Pro
Affected Parties
Neuraxpharm PharmaceuticalsPatients using Dimethyl Fumarate+1 more…
Tags
medicinal products,marketing authorization,European Commission…